ESAB was acquired by Colfax in 2012 and spun off as a stand-alone company in 2022. ESAB staged an impressive turnaround, more than doubling its adjusted operating margin from 7% in 2012 to 16.7% in ...

Respiratory diseases are a challenging problem to treat. Inhalable medicines are a promising solution that depend on the ability to deliver tiny particles known as aerosols to the correct location in ...